Hendrik Kroening

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Xavier Pivot, Joseph Gligorov, Volkmar Müller et al. · Annals of Oncology · 2014 · 176 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial

Hans‐Joachim Schmoll, Burghardt Wittig, Dirk Arnold et al. · Journal of Cancer Research and Clinical Oncology · 2014 · 97 citations · Full text

Medicine, Oncology, Pharmacology +16

295 Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial

Axel Grothey, Kim Jordan, O Kellner et al. · European Journal of Cancer Supplements · 2003 · 63 citations

Medicine, Oncology, Pharmacology +14

Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study

Eric Van Cutsem, Iwona Danielewicz, Mark Saunders et al. · Annals of Oncology · 2020 · 61 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Phase III trial of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (MAYO) vs. weekly oxaliplatin (OXA) plus high dose 24h 5-FU infusion/FA in patients with advanced colorectal cancer (CRC)

Axel Grothey, T. Buechele, Hendrik Kroening et al. · European Journal of Cancer · 2001 · 57 citations

Medicine, Oncology, Pharmacotherapy +16